Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Open-Label Multi-Institution Phase II Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC)

NCT00881751 is registered in ClinicalTrials.gov with Medical University of South Carolina as lead sponsor.

NCT NCT00881751
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00881751 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Open-Label Multi-Institution Phase II Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC)
Lead sponsor
Medical University of South Carolina
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2009
Completion date
February 28, 2017
Enrollment
95 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

liver cancer